Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Merrill Ups Watson Pharmaceuticals to 'Buy'


Merrill Lynch upgraded Watson Pharmaceuticals (WPI) to buy from neutral, and set a $40 target.

Analyst Greg Gilbert says he thinks investors are looking for ideas for new money, and are particularly focused on stocks that have reasonable valuations. Based on an improved fundamental outlook and compelling valuation, he thinks Watson is poised for a run.

Two key concerns had been the lack of a chief financial officer, and a relatively small generic pipeline relative to Watson's size. On Monday, Watson announced it was hiring a new CFO, and expanded its deal with Cipla, which greatly expanded Watson's generic pipeline.

Gilbert says the company now has 20 abbreviated new-drug applications, and 60 generic products under development. He sees $1.81 2003 earnings per share, and $2.00 for 2004.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus